FDA draft guidance clarifies risk disclosures in drug ads

FDA is seeking comments on revised draft guidance clarifying requirements for disclosures in consumer-directed print prescription drug advertisements and promotional materials,

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE